Quick Answer
Stoke Therapeutics, Inc. reported Net Income Loss of -$6.89 million for the year ending 2025.
- Stoke Therapeutics, Inc. showed an increase of +92.3% in Net Income Loss from 2024 to 2025.
- This data is from Stoke Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Stoke Therapeutics, Inc.'s Net Income Loss has grown by 45.0%.
- Historical annual values: Fiscal year 2025: -$6.89 million | Fiscal year 2024: -$88.98 million | Fiscal year 2023: -$104.70 million | Fiscal year 2022: -$101.07 million | Fiscal year 2021: -$85.81 million | Fiscal year 2020: -$52.24 million | Fiscal year 2019: -$32.33 million | Fiscal year 2018: -$12.52 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: